OBJECTIVE: The aim of this study was to evaluate the potential of FDG-PET in the differential diagnosis of CNS lesions in patients with AIDS, particularly to differentiate between toxoplasmosis and lymphoma. MATERIALS AND METHODS: We examined 11 AIDS patients, 6 with toxoplasmosis, 1 with a tuberculoma, and 4 with a primary CNS lymphoma. The FDG uptake within the lesion was compared with the uptake in a contralateral brain area [standardized uptake value (SUV)]. RESULTS: In all subjects with cerebral infections (toxoplasmosis, tuberculoma), the SUV ratio was significantly (p < 0.05) lower than the SUV ratio in patients with lymphoma (range of 0.3-0.7 vs. 1.7-3.1) with no overlap of the uptake values. CONCLUSION: In conclusion, FDG-PET may help to characterize these lesions metabolically and play an important role in the clinical management of AIDS patients with CNS involvement.
OBJECTIVE: The aim of this study was to evaluate the potential of FDG-PET in the differential diagnosis of CNS lesions in patients with AIDS, particularly to differentiate between toxoplasmosis and lymphoma. MATERIALS AND METHODS: We examined 11 AIDSpatients, 6 with toxoplasmosis, 1 with a tuberculoma, and 4 with a primary CNS lymphoma. The FDG uptake within the lesion was compared with the uptake in a contralateral brain area [standardized uptake value (SUV)]. RESULTS: In all subjects with cerebral infections (toxoplasmosis, tuberculoma), the SUV ratio was significantly (p < 0.05) lower than the SUV ratio in patients with lymphoma (range of 0.3-0.7 vs. 1.7-3.1) with no overlap of the uptake values. CONCLUSION: In conclusion, FDG-PET may help to characterize these lesions metabolically and play an important role in the clinical management of AIDSpatients with CNS involvement.
Authors: Paul C Schroeder; M Judith Donovan Post; Elizabeth Oschatz; Alfred Stadler; Jocelyn Bruce-Gregorios; Majda M Thurnher Journal: Neuroradiology Date: 2006-09-01 Impact factor: 2.804
Authors: Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2009-04-07 Impact factor: 9.236
Authors: Scarlett Lewitschnig; Keerti Gedela; Martina Toby; Ranjababu Kulasegaram; Mark Nelson; Michael O'Doherty; Gary J R Cook Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-18 Impact factor: 9.236